Insights provides context and perspective about key pharmacy trends and issues

Specialty
While the launch time is uncertain, potential PAH generics could give payors greater cost control opportunities for a complex, expensive condition requiring lifelong treatment. More
Briefing
Specialty
Learn more about how CVS Health plans to reshape kidney care by helping improve care and quality of life for patients with kidney disease. More
Video
Specialty
CVS Health is utilizing our integrated model and expertise in holistic patient care to an area of unmet clinical need — chronic kidney disease and end-stage renal disease – to reshape... More
Feature
Specialty
Kidney disease is highly prevalent and caring for members with kidney disease is highly complex and expensive. Learn more about this complex, expensive condition. More
Infographic
Specialty
Gene therapies bring hope for patients with conditions with few or no treatments, but also other considerations including safety and cost. More
Feature
Future of HIV Treatment
Specialty
HIV drugs are a $17 billion market and the pipeline has seen dramatic shifts in recent years. Ongoing monitoring, effective utilization management, and a focus on adherence can help control... More
Briefing
Specialty
Blockbuster cancer drug Zytiga may become first-line treatment for patients with metastatic, castration-resistant cancer, greatly expanding its market and cost impact. More
Feature
Specialty
Wearable health trackers, secure texting, and new biomarker technology allow for increased patient engagement and better health outcomes. More
Briefing
Specialty
Multiple Sclerosis is a $19 billion market worldwide, and the third most expensive specialty drug spend category. Recently approved Ocrevus is likely to add to cost of treatment and needs... More
Briefing
Specialty
The specialty pipeline has many promising new drugs. The complexity and personalized nature of some medications require that they be managed under the medical benefit. More
Briefing